More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...